Acurx Pharmaceuticals, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Acurx Pharmaceuticals, Inc. (ACXP) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $2.36 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-08-13
- Acurx Pharmaceuticals, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2025-03-31 was $0.80, a 74.60% decline year-over-year.
- Acurx Pharmaceuticals, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-03-31 was $3.15, a 7.62% decline year-over-year.
- Acurx Pharmaceuticals, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-03-31 was $3.41, a 23.20% decline year-over-year.
- Acurx Pharmaceuticals, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2022-03-31 was $4.44.
- Acurx Pharmaceuticals, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $15.94, a 414.19% increase from fiscal 2024.
- Acurx Pharmaceuticals, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $3.10, a 7.46% decline from fiscal 2023.
- Acurx Pharmaceuticals, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $3.35, a 21.36% decline from fiscal 2022.
- Acurx Pharmaceuticals, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $4.26, a 9.75% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 1 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $2.36 10-Q · filed 2026-08-13 | |||||
| 2025-12-31 | $15.94 10-K · filed 2026-03-12 | |||||
| 2025-09-30 | $15.94 10-Q · filed 2025-11-12 | |||||
| 2025-06-30 | $15.94 10-Q · filed 2025-08-11 | |||||
| 2025-03-31 | $0.80 10-Q · filed 2025-05-12 | |||||
| 2024-12-31 | $3.10 10-K · filed 2025-03-17 | |||||
| 2024-09-30 | $3.10 10-Q · filed 2024-11-12 | |||||
| 2024-06-30 | $3.10 10-Q · filed 2024-08-08 | |||||
| 2024-03-31 | $3.15 10-Q · filed 2024-05-14 | |||||
| 2023-12-31 | $3.35 10-K · filed 2024-03-15 | |||||
| 2023-09-30 | $3.35 10-Q · filed 2023-11-13 | |||||
| 2023-06-30 | $3.35 10-Q · filed 2023-08-11 | |||||
| 2023-03-31 | $3.41 10-Q · filed 2023-05-12 | |||||
| 2022-12-31 | $4.26 10-K · filed 2023-03-15 | |||||
| 2022-09-30 | $4.26 10-Q · filed 2022-11-10 | |||||
| 2022-06-30 | $4.67 10-Q · filed 2022-08-12 | $4.26 10-Q · filed 2022-08-12 | ||||
| 2022-04-30 | $3.79 10-Q · filed 2022-08-12 | |||||
| 2022-03-31 | $4.69 10-Q · filed 2022-05-10 | $4.44 10-Q · filed 2022-05-10 | ||||
| 2021-12-31 | $4.72 10-K · filed 2022-03-16 | |||||
| 2021-09-30 | $6.21 10-Q · filed 2021-11-12 | $4.72 10-Q · filed 2021-11-12 | ||||
| 2021-06-30 | $6.26 10-Q · filed 2021-08-13 | $6.26 10-Q · filed 2021-08-13 | ||||
| 2020-12-31 | $6.21 10-K · filed 2022-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B |